USX:CABA - Cabaletta Bio Inc Cabaletta Bio Inc
Sector: Health Care, Industry: Biotechnology
Next Earnings: 9 May 2024
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 17.15    +0.19 (+1.12%)

27 Mar 2024


Loading...
Loading...
Loading...

General

CEO: Dr. Steven A. Nichtberger M.D.

IPO: 2019-10-25

Headquarters: US

Employees: 77

Homepage

Description

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies  CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Your Holdings
Dashboard
Portfolio
Options

Tools
Screener
Watchlist
Alerts
Notes
Community
Forum
Blog
YouTube
Shared Portfolios
Shared Screeners

Collab with Brokerages
Moomoo x StocksCafe
Tiger x StocksCafe

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Bombay
National (India)
Indexes
Singapore Savings Bonds
Singapore T-Bills
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
YouTube
Server Fundamental

About · FAQs · StocksCafe © 2024 · Privacy · Terms